Article Information
- Received April 20, 2012
- Revision received October 10, 2012
- Accepted October 16, 2012
- First published November 28, 2012.
- Version of record published November 28, 2012.
Author Information
- Guillaume M. Fortin1,
- Marie-Josée Bourque1,
- Jose Alfredo Mendez1,
- Damiana Leo1,
- Karin Nordenankar6,
- Carolina Birgner6,
- Emma Arvidsson6,
- Vladimir V. Rymar5,
- Noémie Bérubé-Carrière2,
- Anne-Marie Claveau1,
- Laurent Descarries2,3,4,
- Abbas F. Sadikot5,
- Åsa Wallén-Mackenzie6, and
- Louis-Éric Trudeau1,4
- 1Department of Pharmacology,
- 2Department of Pathology and Cell Biology,
- 3Department of Physiology, and
- 4Groupe de Recherche sur le Système Nerveux Central, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada H3C 3J7,
- 5Montreal Neurological Institute, Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada H3A 2B4, and
- 6Unit of Developmental Genetics, Department of Neuroscience, Uppsala University, S-751 24 Uppsala, Sweden
Author contributions
Author contributions: L.D., A.W.-M., and L.-E.T. designed research; G.M.F., M.-J.B., J.A.M., D.L., K.N., C.B., E.A., V.V.R., N.B.-C., and A.-M.C. performed research; G.M.F., M.-J.B., J.A.M., D.L., K.N., C.B., E.A., V.V.R., N.B.-C., L.D., A.F.S., and L.-E.T. analyzed data; G.M.F., L.D., A.F.S., A.W.-M., and L.-E.T. wrote the paper.
Disclosures
- Received April 20, 2012.
- Revision received October 10, 2012.
- Accepted October 16, 2012.
This work was funded by grants to L.-E.T from the Canadian Institutes of Health Research (CIHR; MOP-106556), the Parkinson Society of Canada and Brain Canada Foundation (Krembil Foundation), and partially supported by CIHR Grants MOP-3544 and MOP-106562 to L.D. L.-É.T. and L.D. also benefited from an infrastructure grant of the Fonds de la recherché en santé du Québec (FRSQ) to the Groupe de Recherche sur le Système Nerveux Central. G.F. received a graduate scholarship from the Parkinson Society of Canada and N.B.-C. was the recipient of a doctoral studentship from FRSQ. D.L. was supported by a postdoctoral fellowship from the Department of Foreign Affairs and International Trade of Canada, and by a postdoctoral fellowship from the FRSQ. Research in A.W.-M.'s laboratory was supported by the Swedish Research Council, the Swedish Brain Foundation, the Åhlén and Wiberg Foundations, the National Board of Health and Welfare, and Uppsala University, Sweden. The Swedish Foundation for International Cooperation in Research and Higher Education (STINT) also provided support for collaboration between L.-E.T.'s and A.W.-M.'s laboratories. A.F.S. was funded by operating grants from the CIHR and Natural Sciences and Engineering Research Council of Canada. We thank Dr. Xiaoxi Zhuang (University of Chicago) for providing the DAT-CRE mice, and Dr. Bradford Lowell (Harvard University Medical School) for providing the VGLUT2 flox/flox mice.
- Correspondence should be addressed to Dr. Louis-Eric Trudeau, Department of Pharmacology, Faculty of Medicine, Université de Montréal, C.P. 6128, Succursale Centre-Ville, Montréal, Québec, H3C 3J7. louis-eric.trudeau{at}umontreal.ca
Online Impact